Moderna Inc (NAS:MRNA)
$ 141.01 8.11 (6.1%) Market Cap: 54.04 Bil Enterprise Value: 43.65 Bil PE Ratio: 0 PB Ratio: 4.21 GF Score: 68/100

Moderna Inc R&D Day Transcript

Sep 09, 2021 / 12:00PM GMT
Release Date Price: $455.92 (+7.81%)
Lavina Talukdar
Moderna, Inc. - Senior VP & Head of IR

Good morning, and welcome. Thank you for joining us on Moderna's Fifth Annual R&D Day. Today, you will be hearing from members of our executive team and from Moderna's therapeutic area heads, highlighting the progress to date on a select number of clinical programs. In addition, we have a key opinion leader in the immuno-oncology space presenting today as well.

Following the formal presentations, we will take your questions during the Q&A session. You can access the press release highlighting the progress and updates announced this morning as well as the presentation slides by going to the Investors section of our website.

On today's call are Stephane Bancel, our Chief Executive Officer; Stephen Hoge, our President; Paul Burton, our Chief Medical Officer; Jackie Miller, Senior Vice President and Therapeutic Area Head of Infectious Diseases; Praveen Aanur, Vice President and Therapeutic Area Head of Oncology; and Ruchira Glaser, Senior Vice President and Therapeutic Area Head of Rare Diseases, Cardiovascular Disease and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot